Research and Markets: PharmaPoint: HIV - France Drug Forecast and Market Analysis to 2022
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130306:nBw065676a DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/965tdr/pharmapoint_hiv) has announced the addition of GlobalData's new report "PharmaPoint: HIV - France Drug Forecast and Market Analysis to 2022" to their offering. GlobalData has released its new Country report, PharmaPoint: HIV - France Drug Forecast and Market Analysis to 2022. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. Atripla was the first single-tablet regimen (STR) to enter France in 2009, ushering in an era of STR development and commercialization. ViiV Healthcare and Gilead Sciences are the main companies pursuing STRs to position themselves as the market leaders in France. Scope - Overview of France including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in France from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting France HIV market. Key Topics Covered: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Disease Overview 4 Disease Management 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/965tdr/pharmapoint_hiv Source: GlobalData Research and Markets Laura Wood, Senior Manager. email@example.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals Copyright Business Wire 2013
- Israel rejects ceasefire plan, source says, as death toll nears 850 |
- Obama tells Central American leaders most children will go home
- First Ebola victim in Sierra Leone capital on the run
- Bad weather seen as probable cause of Air Algerie crash
- EU edges to economic sanctions on Russia but narrows scope |